ABSTRACT
Pancreatic cancer is one of the deadliest diseases largely due to difficulty in early diagnosis and the lack of effective treatments. KRAS is mutated in more than 90% of pancreatic cancer patients, and oncogenic KRAS contributes to pancreatic cancer tumorigenesis and progression. In this report, using an oncogenic KRAS V12 -based pancreatic cancer cell model, we developed a chemical genetic screen to identify small chemical inhibitors that selectively target pancreatic cancer cells with gain-of-function KRAS mutation. After screening ~3,200 compounds, we identified one compound that showed selective synthetic lethality against the KRAS V12 transformed human pancreatic ductal epithelial cell over its isogenic parental cell line. These selective KRAS V12 -synthetic lethal compounds may serve as leads for subsequent development of clinically-effective treatments for pancreatic cancer.
INTRODUCTION
Pancreatic cancer (PC) is the fourth-leading cause of cancer-related death in the US, with a 5-year survival rate of less than 4% (16;17) . PC is resistant to most forms of treatments such as chemotherapy, radiation, and combination therapies that are effective in other tumors. The refractory nature of this disease clearly underscores the need for novel drug discovery research that specifically targets the genetic makeup of pancreatic ductal adenocarcinoma (PDA).
Extensive histopathological and genetic studies have led to a PDA tumor progression model in which the pancreatic ductal epithelium progresses from normal to increased grades of pancreatic intraepithelial neoplasias (PanINs), to invasive adenocarcinoma (14) . In parallel with progressive stages of morphological changes is sequential accumulation of genetic alterations in KRAS and tumor suppressors INK4A, TP53 and SMAD4/DPC4. Activating KRAS mutations represent one of the earliest genetic changes associated with the transformation of normal ductal epithelium. KRAS mutations have been detected in pancreatic duct lesions with minimal cytological and architectural atypia, and, occasionally, in the histologically normal pancreas (4;21;24;25;27) . The frequency of KRAS mutations correlates with disease progression, reaching almost 100% in PDA. Targeted endogenous expression of an oncogenic KRAS allele in the mouse pancreas is sufficient to drive the development of PanINs, and subsequently, at low frequency, the progression to both locally invasive adenocarcinoma and metastatic disease with sites of spread exactly as found in human pancreatic cancer (1;12;13). These observations suggest that KRAS plays an essential role in the initiation, progression and maintenance of PDA.
Because of its critical importance in PDA development, oncogenic KRAS represents a good target for therapeutic intervention. Consistent with this notion, siRNA specifically targeting oncogenic KRAS allele induces growth inhibition and apoptosis in pancreatic cancer cell lines harboring KRAS mutation. However, small molecules that inhibit RAS activation by targeting its posttranscriptional modification have so far yielded little success as these compounds also affect cellular targets/pathways other than RAS. On the other hand, novel cell-based screens that target the Achilles' heel of PC (the dependence of PC cell's survival on oncogenic RAS) may lead to the identification of effective inhibitors for PC. Recently, a chemical genetic screening strategy has been developed that involves searching for synthetic lethal antitumor agents that selectively kill tumor cells with specific genotypes such as, the presence of a specific oncoprotein or the loss of a specific tumor suppressor (6;20) .
In this report, we developed a chemical genetic screen using an oncogenic KRAS-based human pancreatic ductal epithelia (HPDE) cancer model. This cell-based assay allowed us to search through existing libraries of small chemical compounds to identify mechanism-based inhibitors that show selective lethality in the presence of oncogenic KRAS alleles.
Those compounds with KRAS V12 -selective lethality may serve as leads for subsequent development of clinically-effective drugs with a favorable therapeutic index for PC.
MATERIALS AND METHODS

Cell lines
Primary human pancreatic ductal epithelial cell (HPDE-c7) immortalized by E6/E7 genes of human papilloma virus (HPV)-16 virus was a gift from Dr. Ming S. Tsao. Stable HPDE-c7-KRAS V12 cell line was generated from HPDE-c7 by the addition of oncogene KRAS V12 using retroviral vector (18) . Parental HPDE-E6E7c7 and HPDEc7-KRAS V12 cells are maintained in keratinocyte-SFM medium supplemented by bovine pituitary extract and epidermal growth factor (Gibco-BRL) at 37 °C and 5% CO 2 .
Compound libraries
Small chemical compounds from the Diversity set (1990 compounds), Mechanistic set (879 compounds), Challenge set (57 compounds), and Natural Product set (235 compounds) were obtained from the Open Chemical Repository of National Cancer Institute Developmental Therapeutics Program (DTP). Compounds were supplied in DMSO in 96-well polypropylene plates and stored at -80°C. Replica daughter plates were generated by diluting original stock plates 10-fold in DMSO and used for screening.
Screening
Assay plates were prepared by seeding cells in 96-well plates (4000 cells/well in 100 µl) using a repetitive dispenser. Columns 2-11 were treated with compounds from a daughter library plate. The final compound concentration in assay plates was 10 µM. Columns 1 and 12 were treated with vehicle and 1 µM Taxol as negative and positive controls, respectively. The assay plates were incubated for 24-48 hrs at 37°C in a humidified incubator containing 5% CO 2 and processed for cell viability assay, as described below.
Alamar Blue cell viability assay
A 100 µl of the cell suspension was seeded per well in duplicates in 96-well microtiter plates (Corning, NY) and treated with compounds. An aliquot of 10 µl of Alamar Blue was added to each well and the plates were incubated for another 4 hrs. Following the incubation, fluorescence intensity was monitored using a SpectraMax M2 microplate reader (Molecular Devices) with excitation and emission wavelengths set at 530 and 590 nm, respectively.
Data Analysis
Mean relative fluorescence units for untreated cells (RFU untreated cell ) were calculated by averaging columns 1 (wells treated with vehicle). Percentage inhibition of each well was calculated as ( (1 − RFU/RFU untreated cell ) ·100). Compounds causing at least 50% inhibition of Alamar Blue signal in the primary screen will be tested for selectivity toward KRAS transformed HPDE cells using HPDE-c7-KRAS V12 and parental HPDE-c7 cells in parallel in 2-fold concentration dilution series to determine the dose response curves. The quality of the Alamar Blue screen assay was determined by the Z' score as described previously (31).
RESULTS
Oncogenic transformation of HPDE by KRAS V12
To target oncogenic KRAS in pancreatic cancer cells, we established an oncogenic KRAS-based human PC model using an immortalized primary HPDE cell line, HPDE-c7. This well-characterized cell line is a near diploid HPDE cell line originally derived from a normal pancreas. While immortalized by E6/E7 genes of human papilloma (HPV)-16 virus, HPDE-c7 is non-tumorigenic and incapable of inducing tumor growth in nude mice (26; 27) . Stable expression of KRAS V12 in HPDE-c7 cells, using a retroviral expression vector, led to transformation of the cell line. The resultant cells, HPDE-c7-KRAS V12 , expressed increased levels of total RAS protein, showed high RAS-GTP activity ( Figure 1A ), and were grown anchorage-independently in soft agar ( Figure 1B) . In addition, expression of KRAS V12 in HPDE-c7 cells also led to an increased activation of its downstream effectors, such as MAPK and AKT. The phospho-MAPK and phospho-AKT levels were enhanced in the HPDE-c7-KRAS V12 cells compared with the parental cells ( Figure 1C ). These observations are in complete agreement with results obtained from an independently established KRAS human PC model using the same HPDE-c7 parental cell line (28).
Development of a cytotoxic assay suitable for highthroughput screen
We selected Alamar Blue-based cytotoxicity assay as our primary assay because Alamar Blue is a non-toxic metabolic indicator of viable cells that becomes fluorescent upon mitochondrial reduction and the assay does not involve washing steps. It is, therefore, easier to adapt to a high-throughput format for handling large volume screening (26) . To establish the optimal assay conditions, we performed the assay under various cell-plating densities and incubation times. As shown in Figure 2 , the assay exhibited wide dynamic ranges for both cell plating density and incubation time. The relative fluorescence readout displayed excellent linear dependence on cell density (0.3 to 22.5×10 3 per well) and time up to 6 hrs. Based on these results, optimal assay conditions were established using 4000 cells/well and 4 hrs incubation time for subsequent screenings. DMSO titration studies suggest that our cell viability assay can tolerate up to 0.5% of DMSO. The robustness and reproducibility of the assay were tested using 0.1% DMSO and Doxorubicin (10 µM) as vehicle and positive controls. An average Z' score of 0.79 was obtained from measurements across the entire plate, which demonstrated robustness of this assay. Similar results were obtained with measurements at various times on different machines, suggesting minimal day-to-day and machine-tomachine variations for our assay. This assay was also adapted to a 384-well format at the San Diego Chemical genomic Center, and an average Z' score of 0.75 was obtained. When our assay was tested using known cytotoxic compounds, such as Doxorubicin or Taxol, reproducible and dose-dependent responses were observed for both HPDE-c7 and HPDE-c7-KRAS V12 cells.
Identification of synthetic lethal compounds selectively against mutant KRAS expressed cells
Using the Alamar Blue based cytotoxic assay, we then carried out a median-throughput chemical screen to identify compounds that selectively kill KRAS V12 transformed cells. The process consists of a three-step screening. Initially, compounds were evaluated in the HPDE-c7-KRAS V12 cell line at a single concentration of 10 µM. After screening four compound libraries, the NCI diversity set (1,990 compounds), Natural product set (235 compounds), Mechanistic set (879 compounds), and Challenge set (57 compounds), we identified a total of 580 compounds that showed >50% growth inhibition activity against the HPDE-c7-KRAS V12 cells at 10 µM (Figure 3) . These compounds were then subjected to the second-step of selectivity screen, in which each compound was tested against both HPDE-c7 and HPDE-c7-KRAS V12 cell lines in parallel at four different concentrations: 20, 10, 5 and 2.5 µM ( Figure 4A ). If a specific compound completely inhibited the growth/survival of both cell lines at 2.5 µM, then further dilutions at lower testing concentrations were used ( Figure 4B ). 24 compounds that inhibited the HPDEc7-KRAS V12 cells 20% more than the control cells at two or more of the four concentrations were selected. These 24 compounds were further evaluated at various concentrations in triplicate to determine their IC 50 against HPDE-c7 and HPDE-c7-KRAS V12 cell lines, respectively. IC 50 values of each compound were determined and used to calculate the selectivity index (IC 50 of HPDE-c7 cells/IC 50 of HPDE-c7-KRAS V12 cells). One compound, SLI501, with a selectivity index >2 was identified. The activity profile of SLI501 in HPDE-c7 and HPDE-c7-KRAS V12 cell lines was shown in Figure 5 . SLI501 has an IC 50 value of 3.6 µM in HPDE-c7-KRAS V12 cells and an IC 50 value of 9.0 µM in HPDE-c7 cells.
DISCUSSION
Although PC is now a well-characterized neoplasm at the genetic level, the prognosis of PC patients is still very poor. This is largely due to the aggressive nature of this disease and the lack of effective therapeutic agents. The refractory nature of PC clearly warrants the need for novel drug discovery research that specifically targets PDA. Molecularly-targeted drug discovery has recently matured as an effective approach for developing cancer therapeutics. This approach directly targets the genetic makeup that is essential for the oncogenic transformation in cancer, but not for normal cells. Targeted therapeutics should be more effective and tolerated with minimal on-target toxicity when compared to traditional cytotoxic compounds. Oncogenes or tumor suppressor genes identified in cancers can be chosen as targets if they prove to be critical for cancer development and survival (3;28). Both structure-based rational design and mechanism-based screening were employed to develop drug candidates (2;3;15;29) . One of the most successful examples of molecularly-targeted anticancer therapeutics is Gleevec, an effective, FDA-approved treatment of chronic myelogenous leukemia (CML) (5) . Gleevec inhibits the breakpoint cluster region-abelsen kinase (BCR-ABL) oncogene which is frequently found in CML and is a major driver for CML initiation and progression (7) .
One important factor that contributes to the success of Gleevec is our deep understanding of the genetic alternations responsible for the formation of CML. In theory, successful molecularly-targeted drug discovery should be possible for cancers with well-defined genetic alterations such as oncogenic KRAS in PC. One major challenge is to design mechanism-based HTS assays that are tailored for targeting the genetic alteration in a specific cancer. Two recent scientific advances in geneticallydefined human cancer cell models and synthetic lethal screening (SLS) using small chemical libraries have significantly facilitated this process. Oncogenic transformation of human primary cells using defined genetic elements allows for the creation of human cancer cell models that recapitulate the genetic and molecular characteristic of human cancers in a tissue-specific manner (10) . SLS is a method originally used to search mutations in a second gene that exert lethality to a specific mutation in a model organism such as yeast (8) . Adaptation of SLS using small chemicals in place of mutation has recently emerged as a powerful drug discovery tool in the postgenomic era (6;9;11;19;28) . A chemical genetic screening coupling genetically-defined cancer models and SLS provides a general approach for screening mechanismbased cancer inhibitors that are selective for specific targets (6;28).
Our genetic defined KRAS-based PC cell model was created from immortalized HPDE cells (18) . Using this KRAS-based PC model, we developed a cell-based HTS assay and uncovered a small chemical compound that selectively inhibits the growth/survival of oncogenic KRAS expressing HPDE cells. Because of the nature of SLS, synthetic lethal compounds may not directly affect the activity of the particular oncogene involved; rather they render cells expressing the oncogene at disadvantage for growth/survival. For example, one SLS has led to the identification of a quinazoline analogue, Erastin that preferentially kills transformed human foreskin fibroblast cells expressing SV40 small T and the RAS V12 oncoproteins (6) . A recent study suggests that Erastin acts through mitochondrial voltage-dependent anion channels (VDACs) and alters the permeability of the outer mitochondrial membrane, causing the generation of oxidative species and subsequent death through an oxidative, non-apoptotic mechanism in cells harbouring oncogenic RAS (30) . The mechanism of action of the compound identified from our SLS is not known. We are in active pursuit of the identity of the molecular target(s) of this compound. In some cases, the protein target of a compound can be identified through affinity chromatography using the compound coupled to a solid phase matrix and mass spectrometry (22;30) . Analysis of gene expression profiles using cDNA microarray between the isogenic cell lines after the treatment with the compounds could also provide some clues about the perturbation of signaling pathways that might be responsible for the selectivity (23).
In summary, Our oncogenic KRAS-based PC model allows us to search through existing libraries of small chemical compounds to identify mechanism-based inhibitors with selective lethality in the presence of oncogenic KRAS, the most frequently mutated allele in PC. Those compounds with KRAS V12 -selective lethality may serve as leads for subsequent development of clinically effective drugs with a favorable therapeutic index for PC.
